Full Press Release Details
Zura Bio Announces Participation in June Investor
Henderson, Nev - May 29, 2024 - Zura
Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodies
for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences
Event: Jefferies Global Healthcare Conference
Details: Michael Howell, Ph.D., Chief Scientific Officer and
Head of Translational Medicine, will participate in one-on-one meetings on Thursday, June 6, 2024, in New York, NY.
Event: Oppenheimer Novel Targets in Immunology Summit
Details: Robert Lisicki, Chief Executive Officer, will participate
in a "Novel Immunological Mechanisms for Dermatological Disorders" panel discussion and one-on-one meetings on Monday, June
24, 2024, in New York, NY.
Zura Bio is a clinical-stage, multi-asset immunology
company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets
which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab
(ZB-106), ZB-168, and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune
and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.
Head of Investor Relations